Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRE-03: Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage TNBC
NCT04427293Phase 1Active, not recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Jul 2020
- Primary completion
- Jul 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenvatinib and pembrolizumab in triple-negative breast cancer (TNBC), sponsored by University of Illinois Chicago. Primary endpoint: Infiltration of CD8+ tumor infiltrating lymphocytes (TILs) (CD45RA-/CD8+/FoxP3-) in primary tumors at 2 years. Started Jul 2020; status: active, not recruiting.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04427293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04427293.